G2211 Is Being Deleted: What Urology Practices Need to Know About the 2027 Modifier Change

QUICK ANSWER

• What is happening to G2211 in 2027? As of the CMS CY 2027 Medicare Physician Fee Schedule proposed rule released July 14, 2026, HCPCS code G2211, the visit complexity add-on for evaluation and management services, is proposed for deletion effective January 1, 2027. CMS would replace it with a modifier, currently designated MOD1, that pays 16 percent of the associated E/M code rather than the current flat rate. Comments on the proposed rule are due September 14, 2026.
• What is changing: G2211 would stop being a standalone code billed alongside an E/M visit. The replacement modifier attaches directly to the E/M code and pays a percentage of that code value, not a fixed dollar amount.
• Who this affects: Every urology practice billing G2211 for longitudinal complex care, including prostate cancer management, chronic BPH follow-up, and stone disease patients, needs to update superbills and PM/EHR systems before January 2027.
• Comment deadline: September 14, 2026. The AUA is submitting formal comments and urges urologists to submit individual comments through the CMS portal before the deadline closes.

What G2211 Actually Does in Urology Billing

G2211 is the HCPCS Level II add-on code for visit complexity inherent to evaluation and management services. CMS created it to compensate physicians for the additional work involved in building and maintaining a longitudinal relationship with patients who have complex medical conditions. In urology, that relationship is the norm rather than the exception. A urologist managing a patient through years of prostate cancer surveillance, recurrent stone disease, or progressive BPH is doing exactly the work G2211 was designed to recognize.

The code was finalized for separate payment in the CY 2021 PFS final rule, delayed by statute, and finally implemented for CY 2025. It can be reported with office and outpatient E/M visits (99202 through 99215) when the visit reflects an ongoing relationship with a patient whose care involves medical decision-making that is informed by that history. It cannot be reported when modifier 25 is appended to the E/M code for a same-day procedure, which is a restriction many urology billing teams still get wrong. Our modifier 25 urology payment guide covers that interaction in detail.

One question we hear constantly from practice managers is whether their team is even capturing G2211 on eligible visits. Across the billing companies we vet, underbilling G2211 is far more common than overbilling it. Many urology practices left the code off their superbills entirely when it was first implemented, and some still have not added it. The result is legitimate revenue that was never claimed.

How Does the G2211 to Modifier Change Affect Payment?

Under the current system, G2211 pays a flat rate regardless of the E/M level billed alongside it. The CY 2026 national payment amount for G2211 is approximately $16.05. Whether the urologist reports a level 3 visit (99213) or a level 5 visit (99215), the G2211 add-on pays the same dollar amount.

Under the proposed 2027 rule, the replacement modifier MOD1 would pay 16 percent of the associated E/M code value. That means the payment scales with the complexity of the visit. A higher-level E/M code produces a higher modifier payment; a lower-level visit produces a lower one. For urology, this creates a split outcome.

The pattern is clear: practices that code most of their complex visits at level 4 or 5 will see a net increase from the modifier change alone. Practices that bill a high volume of level 3 visits with G2211 will see a small decrease. In our experience matching providers with billing partners, most urology practices skew toward level 4 and 5 for the patients who qualify for G2211, because the clinical complexity that triggers the code also drives the MDM that supports a higher E/M level. But practices need to run the numbers against their own payer mix to know where they land.

These estimates use the CY 2026 non-QPP conversion factor of $33.40 and the proposed 16 percent modifier rate. Final values depend on the CY 2027 conversion factor, which CMS has proposed at $32.84 for non-QPP clinicians, a 1.68 percent decrease from 2026 that reflects the expiration of the temporary 2.5 percent statutory payment increase from the One Big Beautiful Bill Act.

Which Urology Encounters Qualify for MOD1?

The replacement modifier carries the same clinical intent as G2211: it compensates for the additional complexity of managing a patient within an ongoing longitudinal relationship. The clinical scenarios that qualify in urology have not changed under the proposal. What changes is only the payment mechanism.

Qualifying encounters include active surveillance visits for prostate cancer patients the urologist has followed for years, BPH medication management where treatment decisions reference a history of symptom progression and prior interventions, recurrent kidney stone patients whose metabolic workup and prevention plan evolve over time, and chronic interstitial cystitis or overactive bladder patients on multi-year treatment regimens. The common thread is that the medical decision-making at the visit draws on a relationship and a clinical history that would not exist in a one-time encounter.

The restriction against reporting with modifier 25 same-day procedures remains. If the urologist performs a cystoscopy under CPT 52000 on the same day as the E/M visit, the E/M visit takes modifier 25 and neither G2211 nor its replacement modifier applies. This is the same rule that exists today, and it is the rule most commonly broken in urology billing.

What Should Urology Practices Do Before January 2027?

The proposed rule is not final, but the operational preparation is the same whether CMS finalizes these changes as proposed or modifies them. Practices that wait for the final rule in November lose two months of lead time. These are the steps to take now.

1. Run a G2211 utilization report. Pull the last 12 months to establish your baseline volume and the E/M levels billed alongside it.
2. Calculate the revenue impact. Apply the 16 percent modifier rate to each E/M level in your report and compare it to the flat-rate G2211 payments you received.
3. Audit your capture rate. Confirm G2211 is being reported on every eligible visit. If your superbill or EHR template does not prompt for it, your baseline is understated and the modifier transition is an opportunity to fix a gap that already exists.
4. Update your PM/EHR system. Inactivate G2211 and add the MOD1 modifier once CMS publishes the final modifier designation, expected in the November 2026 final rule.
5. Brief your coding staff on documentation. The modifier carries the same criteria as G2211, but practices that have been reporting the code without documenting the longitudinal relationship in the note are exposed to audit risk regardless of the payment change.
6. Submit comments to CMS before September 14, 2026. The AUA is submitting organizational comments and has published guidance for individual urologists.

Common Mistakes Practices Make with G2211 Today

The transition to a modifier is an opportunity to fix errors that have been leaking revenue since G2211 was implemented. These are the patterns we see most often across the billing companies we vet.

• Failing to add G2211 to the superbill at all. Many practices never updated their encounter forms when the code went live in 2025, which means every eligible visit since then has been underbilled.
• Reporting G2211 alongside modifier 25. Billing it on visits where modifier 25 is appended for a same-day procedure is a denial trigger and an audit flag. The two are mutually exclusive.
• Applying G2211 to new patient visits. Reporting it with 99202 through 99205 without a documented prior relationship misuses the code. It is designed for longitudinal care, and a first visit, by definition, has no history to draw on.
• Skipping the documentation of the longitudinal relationship. The code or modifier is defensible only if the note explains how the patient history and the ongoing relationship informed the medical decision-making at this visit.

Providers often come to us after discovering they have been either missing G2211 entirely or reporting it incorrectly for months. Both cost money, and both are fixable with a billing partner who audits the code as part of routine claim scrubbing.

Where G2211 Fits in the 2027 Payment Picture

The G2211 deletion is one piece of a larger proposed payment shift for 2027. The AUA estimates a net negative 2 percent impact on total Medicare charges for urology if the proposed rule is finalized as written. That estimate includes the conversion factor decrease, the proposed 50 percent payment reduction for same-day E/M visits billed with procedures, the practice expense methodology changes, and the G2211 modifier transition.

For a detailed breakdown of the 2027 conversion factor and reimbursement changes affecting urology, see our urology reimbursement 2027 Medicare fee schedule guide. The G2211 change is distinct because it affects coding workflows, not just payment amounts. Practices that prepare for the modifier transition now will have one less disruption to absorb when the final rule drops in November.

Frequently Asked Questions

Next Steps

• Understand the modifier 25 restrictions that carry forward. See our modifier 25 urology payment guide.
• Review the full 2027 reimbursement landscape. See our urology reimbursement 2027 Medicare fee schedule guide.
• Need help preparing your billing operations for 2027? Get matched with a vetted urology billing partner who tracks CMS changes so your team does not have to.

CPT codes and descriptors are maintained by the American Medical Association and HCPCS Level II codes are maintained by CMS. Both are provided here for reference. The CY 2027 Medicare Physician Fee Schedule changes described here are proposed and not final. Payment amounts, modifier designations, and effective dates may change in the final rule, so verify against the published final rule, your Medicare contractor guidance, and payer policies before billing.